JP2024534468A - Ｃａｉｘ標的化ｉｌ－１２融合タンパク質およびそれらの使用方法 - Google Patents

Ｃａｉｘ標的化ｉｌ－１２融合タンパク質およびそれらの使用方法 Download PDF

Info

Publication number
JP2024534468A
JP2024534468A JP2024517044A JP2024517044A JP2024534468A JP 2024534468 A JP2024534468 A JP 2024534468A JP 2024517044 A JP2024517044 A JP 2024517044A JP 2024517044 A JP2024517044 A JP 2024517044A JP 2024534468 A JP2024534468 A JP 2024534468A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
hil
polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534468A5 (https=
JPWO2023043978A5 (https=
Inventor
バトナーゲル，ジャヤ
ヴィタル ゴスワミ，アルビンド
クマル トリプラナ，ハリシュ
ナイル，プラディップ
メラルコード サブバラマン，ラマクリシュナン
ラム クリシン，シヴ
レディ ボレディ，スリニバス
ナイル，レシュミ
ケー． ヴァーシュニー，アヴァニッシュ
タン，セング－ライ
Original Assignee
ビカラ セラピューティクス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビカラ セラピューティクス インコーポレーテッド filed Critical ビカラ セラピューティクス インコーポレーテッド
Publication of JP2024534468A publication Critical patent/JP2024534468A/ja
Publication of JP2024534468A5 publication Critical patent/JP2024534468A5/ja
Publication of JPWO2023043978A5 publication Critical patent/JPWO2023043978A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2024517044A 2021-09-17 2022-09-16 Ｃａｉｘ標的化ｉｌ－１２融合タンパク質およびそれらの使用方法 Pending JP2024534468A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245523P 2021-09-17 2021-09-17
US63/245,523 2021-09-17
PCT/US2022/043762 WO2023043978A2 (en) 2021-09-17 2022-09-16 Caix targeting il-12 fusion proteins and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024534468A true JP2024534468A (ja) 2024-09-20
JP2024534468A5 JP2024534468A5 (https=) 2025-09-04
JPWO2023043978A5 JPWO2023043978A5 (https=) 2025-09-04

Family

ID=85603506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517044A Pending JP2024534468A (ja) 2021-09-17 2022-09-16 Ｃａｉｘ標的化ｉｌ－１２融合タンパク質およびそれらの使用方法

Country Status (11)

Country Link
US (1) US20240392031A1 (https=)
EP (1) EP4402158A4 (https=)
JP (1) JP2024534468A (https=)
KR (1) KR20240161081A (https=)
CN (1) CN118369331A (https=)
AU (1) AU2022345103A1 (https=)
CA (1) CA3232632A1 (https=)
IL (1) IL311442A (https=)
MX (1) MX2024003275A (https=)
WO (1) WO2023043978A2 (https=)
ZA (1) ZA202402034B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111630062A (zh) 2017-11-28 2020-09-04 中外制药株式会社 具有可调节的配体结合活性的配体结合分子
WO2025012105A2 (en) * 2023-07-07 2025-01-16 Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern Muteins of human interleukin 12
WO2025101133A1 (en) * 2023-11-10 2025-05-15 Agency For Science, Technology And Research Interleukin-12 variants and medical uses thereof
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins
WO2025205534A1 (ja) * 2024-03-25 2025-10-02 積水メディカル株式会社 免疫測定方法、精度管理方法、標準試料及び免疫測定試薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620648B1 (pt) * 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
IL297186A (en) * 2020-04-17 2022-12-01 Univ Leland Stanford Junior Transgenic il-12 and il-23 polypeptides and their uses

Also Published As

Publication number Publication date
CA3232632A1 (en) 2023-03-23
MX2024003275A (es) 2024-05-07
EP4402158A4 (en) 2025-07-30
AU2022345103A1 (en) 2024-03-28
WO2023043978A3 (en) 2023-09-28
US20240392031A1 (en) 2024-11-28
CN118369331A (zh) 2024-07-19
ZA202402034B (en) 2025-06-25
KR20240161081A (ko) 2024-11-12
WO2023043978A2 (en) 2023-03-23
IL311442A (en) 2024-05-01
EP4402158A2 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
US20240392031A1 (en) Caix targeting il-12 fusion proteins and methods of use thereof
US20250163155A1 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
US20250019451A1 (en) Anti-ccr8 antibodies and uses thereof
WO2023116880A1 (en) Anti-ccr8 antibodies and uses thereof
CN104884617A (zh) 抗folr1抗体
JP2008531557A (ja) 生物活性を調節するための二重特異性結合剤
CN112739379A (zh) 包含OX40抗原结合位点的Fc结合片段
CN110366561A (zh) 免疫应答的条件性激动剂
JP2022509454A (ja) 癌の処置法
US20230364255A1 (en) Transglutaminase-mediated conjugation
EP4646439A1 (en) Antigen-binding molecules
TW202426498A (zh) Ccr8抗體之醫藥用途及給藥計劃
EP4703389A1 (en) Anti-ptk7 antibody and uses thereof
US20210277139A1 (en) Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
CN115916250A (zh) 用于治疗表达cd90和cd326的癌症的组合物和方法
KR20240058149A (ko) Vista 항원-결합 분자를 사용한 암의 치료 및 예방
US20240228620A1 (en) Multispecific proteins and related methods
WO2022116079A1 (zh) 一种抗ceacam5的人源化抗体及其制备方法和用途
WO2024008190A1 (en) Anti-lilrb2 antibodies and uses thereof
TW202400662A (zh) 結合ｐｄ－ｌ１和ｃｌｄｎ１８．２的抗體及其用途
HK40114345A (zh) Caix靶向型il-12融合蛋白及其使用方法
TWI853396B (zh) 跨膜和盤繞結構域家族3的特異性抗體及其用途
US20250197507A1 (en) Cd161 binding proteins and related methods
US20250109203A1 (en) Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
HK40121523A (zh) 多特异性蛋白及相关方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240517

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250827